Helicobacter pylori Infection Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Epidemiology, Medication, NDA Approvals, Pipeline, Therapeutics and Companies by DelveInsight

Helicobacter pylori Infection Companies working in the treatment market are RedHill Biopharma, Phathom Pharmaceuticals, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvise Pharmaceuticals, AbbVie, TenNor Therapeutics, Nexbiome therapeutics, Cinclus Pharma, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others.
(Albany, USA) DelveInsight's "Helicobacter pylori Infection Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Helicobacter pylori Infection, historical and forecasted epidemiology as well as the Helicobacter pylori Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Helicobacter pylori Infection market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Helicobacter pylori Infection market size from 2020 to 2034, segmented by seven major markets. The Helicobacter pylori Infection Market Report also covers current Helicobacter pylori Infection treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Helicobacter pylori Infection market.

To Know in detail about the Helicobacter pylori Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Helicobacter pylori Infection Market Forecast [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Helicobacter pylori Infection Market Report:

*
The Helicobacter pylori Infection market size was valued approximately USD 2,672 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In November 2024, TenNor Therapeutics has revealed that its antibiotic candidate, rifasutenizol, successfully met all primary endpoints in a Phase III trial, surpassing the current standard of care (SoC). The multicenter, randomized, double-blind, controlled trial (NCT05857163) demonstrated that rifasutenizol triple therapy achieved an eradication rate of over 90%, outperforming bismuth-containing quadruple therapy (BQT), the current control, in treating Helicobacter pylori (H. pylori) infection, a prevalent bacterial infection that can lead to stomach ulcers.

*
The market size for Helicobacter pylori infection in the US was around USD 1,064.8 million in 2022, and it is expected to grow driven by rising disease awareness and the introduction of emerging therapies.

*
The total market size for the EU4 and the UK was estimated at approximately USD 1,028.3 million in 2022, accounting for nearly 38% of the total market revenue across the 7MM.

*
According to the analysis, in the US, clarithromycin-based triple therapy held the second-largest market share among the currently used therapies, generating approximately USD 351.0 million in revenue in 2022.

*
In 2022, Japan recorded a revenue of approximately USD 579.4 million, representing the second-largest market size for Helicobacter pylori Infection among the 7MM, with significant growth expected by 2034.

*
In 2022, the total diagnosed prevalent cases of Helicobacter pylori infection across the 7MM were estimated to be around 321,217,226, with the US contributing approximately 37%, EU4 and the UK accounting for about 43%, and Japan representing around 20% of the total diagnosed cases.

*
In 2022, the US recorded approximately 118,650,370 total diagnosed prevalent cases of Helicobacter pylori infection, which are anticipated to rise throughout the study period as disease awareness and diagnosis improve.

*
According to the analysis, EU4 and the UK had approximately 138,397,508 diagnosed prevalent cases of Helicobacter pylori infection in 2022. These figures are projected to change throughout the study period (2020-2034).

*
Key Helicobacter pylori Infection Companies: RedHill Biopharma, Phathom Pharmaceuticals, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvise Pharmaceuticals, AbbVie, TenNor Therapeutics, Nexbiome therapeutics, Cinclus Pharma, Elpen Pharmaceutical, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others

*
Key Helicobacter pylori Infection Therapies: TALICIA (RHB-105), VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, TAKECAB (vonoprazan), PYLERA, Rifasutenizole (TNP-2198), BGA-1901, Linaprazan glurate, Esomeprazole, TNP-2198, Vonoprazan, Tegoprazan, Levofloxacin, Lansoprazole (Lanton), Vonoprazan, RHB-105, rabeprazole sodium, TAK-438, Ilaprazole + Amoxicillin, Omeprazole, amoxicillin, clarithromycin, and others

*
The Helicobacter pylori Infection epidemiology based on gender analyzed that there is a higher male preponderance in the prevalence of H. pylori infection

*
The Helicobacter pylori Infection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Helicobacter pylori Infection pipeline products will significantly revolutionize the Helicobacter pylori Infection market dynamics.

Helicobacter pylori Infection Overview

Helicobacter pylori (H. pylori) infection is a common bacterial infection that affects the stomach lining, often leading to gastrointestinal disorders such as gastritis, peptic ulcers, and, in severe cases, gastric cancer. H. pylori is a spiral-shaped, gram-negative bacterium that survives in the acidic environment of the stomach by producing urease, an enzyme that neutralizes stomach acid. The infection is primarily transmitted through oral-oral or fecal-oral routes and is more prevalent in developing regions with poor sanitation.

Many individuals with H. pylori infection remain asymptomatic; however, symptoms can include abdominal pain, bloating, nausea, loss of appetite, and indigestion. Chronic infection can lead to complications such as peptic ulcer disease (PUD) and an increased risk of gastric malignancies. Diagnosis involves non-invasive tests like the urea breath test, stool antigen test, or serology, and invasive methods such as endoscopy with biopsy.

Treatment typically consists of triple or quadruple therapy, including proton pump inhibitors (PPIs) and a combination of antibiotics (clarithromycin, amoxicillin, metronidazole, or tetracycline) to eradicate the infection. The rise of antibiotic-resistant H. pylori strains has led to ongoing research for novel treatment approaches, including probiotics and new antimicrobial agents, to improve eradication rates and patient outcomes.

Get a Free sample for the Helicobacter pylori Infection Market Report:

https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market [https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Helicobacter pylori Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Helicobacter pylori Infection Epidemiology Segmentation:

The Helicobacter pylori Infection market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Diagnosed Prevalent Cases of H. pyloriGender-specific Diagnosed Prevalent

*
Cases of H. pylori infection in the 7MM infection in the 7MM

*
Age-specific Diagnosed Prevalent Cases of H. pylori infection in the 7MM

Download the report to understand which factors are driving Helicobacter pylori Infection epidemiology trends @ Helicobacter pylori Infection Epidemiology Forecast [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Helicobacter pylori Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Helicobacter pylori Infection market or expected to get launched during the study period. The analysis covers Helicobacter pylori Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Helicobacter pylori Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Helicobacter pylori Infection Therapies and Key Companies

*
TALICIA (RHB-105): RedHill Biopharma

*
VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK: Phathom Pharmaceuticals

*
TAKECAB (vonoprazan): Takeda Pharmaceutical/Otsuka Pharmaceutical

*
PYLERA: Juvise Pharmaceuticals/AbbVie

*
Rifasutenizole (TNP-2198): TenNor Therapeutics

*
BGA-1901: Nexbiome therapeutics

*
Linaprazan glurate: Cinclus Pharma

*
Esomeprazole: Elpen Pharmaceutical

*
TNP-2198: TenNor Therapeutics

*
Vonoprazan: Phathom Pharmaceuticals

*
Tegoprazan: HK inno.N Corporation

*
Levofloxacin: Deva Holding A.S.

*
Lansoprazole (Lanton): Meridian Bioscience, Inc.

*
Vonoprazan: Takeda

*
RHB-105: RedHill Biopharma

*
rabeprazole sodium: Janssen Cilag Pharmaceutica

*
TAK-438: Takeda

*
Ilaprazole + Amoxicillin: Il-Yang Pharm

*
Omeprazole, amoxicillin, clarithromycin: Forest Laboratories

Discover more about therapies set to grab major Helicobacter pylori Infection market share @ Helicobacter pylori Infection Treatment Market [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Helicobacter pylori Infection Market Strengths

*
High prevalence of H. pylori and increasing awareness about the infections among people will help drive the H. pylori market.

*
Several regimens such as bismuth, sequential therapy, concomitant therapy, and others have become available which will help improve the treatment and overcome the limitations of first-line Clarithromycin-based triple therapy

Helicobacter pylori Infection Market Opportunities

*
Development of novel therapeutic approaches considering the increasing resistance rates despite the use of combined broad-spectrum antibiotics, bismuth, and acid inhibitors.

*
To adapt clinical trials with a focus on achieving high cure rates to ensure antimicrobial stewardship

Scope of the Helicobacter pylori Infection Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Helicobacter pylori Infection Companies: RedHill Biopharma, Phathom Pharmaceuticals, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvise Pharmaceuticals, AbbVie, TenNor Therapeutics, Nexbiome therapeutics, Cinclus Pharma, Elpen Pharmaceutical, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others

*
Key Helicobacter pylori Infection Therapies: TALICIA (RHB-105), VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, TAKECAB (vonoprazan), PYLERA, Rifasutenizole (TNP-2198), BGA-1901, Linaprazan glurate, Esomeprazole, TNP-2198, Vonoprazan, Tegoprazan, Levofloxacin, Lansoprazole (Lanton), Vonoprazan, RHB-105, rabeprazole sodium, TAK-438, Ilaprazole + Amoxicillin, Omeprazole, amoxicillin, clarithromycin, and others

*
Helicobacter pylori Infection Therapeutic Assessment: Helicobacter pylori Infection current marketed and Helicobacter pylori Infection emerging therapies

*
Helicobacter pylori Infection Market Dynamics: Helicobacter pylori Infection market drivers and Helicobacter pylori Infection market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Helicobacter pylori Infection Unmet Needs, KOL's views, Analyst's views, Helicobacter pylori Infection Market Access and Reimbursement

To know more about Helicobacter pylori Infection companies working in the treatment market, visit @ Helicobacter pylori Infection Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Helicobacter pylori Infection Market Report Introduction

2. Executive Summary for Helicobacter pylori Infection

3. SWOT analysis of Helicobacter pylori Infection

4. Helicobacter pylori Infection Patient Share (%) Overview at a Glance

5. Helicobacter pylori Infection Market Overview at a Glance

6. Helicobacter pylori Infection Disease Background and Overview

7. Helicobacter pylori Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Helicobacter pylori Infection

9. Helicobacter pylori Infection Current Treatment and Medical Practices

10. Helicobacter pylori Infection Unmet Needs

11. Helicobacter pylori Infection Emerging Therapies

12. Helicobacter pylori Infection Market Outlook

13. Country-Wise Helicobacter pylori Infection Market Analysis (2020-2034)

14. Helicobacter pylori Infection Market Access and Reimbursement of Therapies

15. Helicobacter pylori Infection Market Drivers

16. Helicobacter pylori Infection Market Barriers

17. Helicobacter pylori Infection Appendix

18. Helicobacter pylori Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=helicobacter-pylori-infection-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-epidemiology-medication-nda-approvals-pipeline-therapeutics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.